A Pilot Neoadjuvant Clinical Trial With Evaluation of Molecular Effects With Sorafenib Tosylate [Sorafenib] for Patients With Stage II or Greater Renal Cell Carcinoma.
Phase of Trial: Phase 0
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 09 Oct 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 05 Mar 2012 Planned end date (Nov 2013) added as reported by ClinicalTrials.gov.